Top

Open Access 27-04-2024 | Multiple Myeloma | REVIEW

Minimal Residual Disease-Adapted Therapy in Multiple Myeloma: Current Evidence and Opinions

Authors: Mina Meseha, James Hoffman, Dickran Kazandjian, Ola Landgren, Benjamin Diamond

Abstract

Purpose of Review

Multiple myeloma (MM) is a biologically heterogeneous malignancy with relatively uniform treatment paradigms. This review aims to assess the growing role of Minimal Residual Disease (MRD) assessment in facilitating response-adapted therapeutic decision making to individualize therapy in MM.

Recent Findings

MRD has been repeatedly demonstrated to provide strong prognostic information, superseding traditional IMWG response criteria. The use of MRD to modulate therapy remains controversial. Here, we review the existing landscape of MRD-adapted trial designs in both induction/consolidation and maintenance settings, including recent data from influential studies and retrospective analyses. We navigate existing data, leverage the increased resolution of longitudinal MRD assessments, and comment on trials in progress to explain our current utilization of MRD in the clinic.

Summary

MRD transcends traditional response assessments by providing a window into disease-treatment interaction over time. As a strong patient-level surrogate, MRD has limited current use in individualizing treatment, but is poised to comprehensively shape treatment strategies at many key points in a patient’s MM course.

Bertamini L, D’Agostino M, Gay F. MRD assessment in multiple myeloma: progress and challenges. Curr Hematol Malig Rep. 2021;16(2):162–71. https://doi.org/10.1007/s11899-021-00633-5.CrossRefPubMed

Flores-Montero J, et al. Next generation flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma. Leukemia. 2017;31(10):2094–103. https://doi.org/10.1038/leu.2017.29.CrossRefPubMedPubMedCentral

Diamond BT, et al. Defining the undetectable: the current landscape of minimal residual disease assessment in multiple myeloma and goals for future clarity. Blood Rev. 2021;46: 100732. https://doi.org/10.1016/j.blre.2020.100732.CrossRefPubMed

Munshi NC, et al. A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma. Blood Adv. 2020;4(23):5988–99. https://doi.org/10.1182/bloodadvances.2020002827.CrossRefPubMedPubMedCentral

Rajkumar SV, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15(12):e538–48. https://doi.org/10.1016/S1470-2045(14)70442-5.CrossRefPubMed

Kostopoulos IV, Ntanasis-Stathopoulos I, Gavriatopoulou M, Tsitsilonis OE, Terpos E. Minimal residual disease in multiple myeloma: current landscape and future applications with immunotherapeutic approaches. Front Oncol. 2020;10. Frontiers Media S.A. https://doi.org/10.3389/fonc.2020.00860.

Paiva B, San-Miguel J, Avet-Loiseau H. MRD in multiple myeloma: does CR really matter? Blood. 2022;140(23):2423–8. https://doi.org/10.1182/blood.2022016170.CrossRefPubMed

Cavo M, et al. Prognostic value of minimal residual disease negativity in myeloma: combined analysis of POLLUX, CASTOR, ALCYONE, and MAIA. Blood. 2022;139(6):835–44. https://doi.org/10.1182/blood.2021011101.CrossRefPubMedPubMedCentral

Jiménez-Ubieto A, et al. Validation of the International Myeloma Working Group standard response criteria in the PETHEMA/GEM2012MENOS65 study: are these times of change? Blood. 2021;138(19):1901–5. https://doi.org/10.1182/blood.2021012319.CrossRefPubMedPubMedCentral

10.

Mailankody S, et al. Minimal residual disease in multiple myeloma: bringing the bench to the bedside. Nat Rev Clin Oncol. 2015;12(5):286–95. https://doi.org/10.1038/nrclinonc.2014.239.CrossRefPubMedPubMedCentral

11.

Puig N, Cedena M-T, Mateos M-V, Lahuerta JJ, Paiva B, San-Miguel JF, Burgos L. Measurable residual disease in multiple myeloma: ready for clinical practice? J Hematol Oncol. 2020. Accessed: Oct. 09, 2023. [Online]. Available: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7310444/.

12.

Derman BA, et al. Prospective trial using multimodal measurable residual disease negativity to guide discontinuation of maintenance therapy in multiple myeloma (MRD2STOP). Blood. 2022;140(Supplement 1):2108–9. https://doi.org/10.1182/blood-2022-158643.CrossRef

13.

Paiva B, et al. MRD dynamics during maintenance for improved prognostication of 1280 patients with myeloma in the TOURMALINE-MM3 and -MM4 trials. Blood. 2023;141(6):579–91. https://doi.org/10.1182/blood.2022016782.CrossRefPubMed

14.

Korde N, et al. Maintenance therapy cessation for sustained MRD negative multiple myeloma patients. Blood. 2022;140(Supplement 1):2397–8. https://doi.org/10.1182/blood-2022-169937.CrossRef

15.

Diamond B, et al. Dynamics of minimal residual disease in patients with multiple myeloma on continuous lenalidomide maintenance: a single-arm, single-centre, phase 2 trial. Lancet Haematol. 2021;8(6):e422–32. https://doi.org/10.1016/S2352-3026(21)00130-7.CrossRefPubMed

16.

de Tute RM, et al. Minimal residual disease after autologous stem-cell transplant for patients with myeloma: prognostic significance and the impact of lenalidomide maintenance and molecular risk. J Clin Oncol. 2022;40(25):2889–900. https://doi.org/10.1200/JCO.21.02228.CrossRefPubMed

17.

Yong K, et al. Risk-adapted therapy directed according to response (RADAR, UK-MRA myeloma XV) - comparing MRD-guided treatment escalation and de-escalation strategies in patients with newly diagnosed myeloma suitable for stem cell transplantation. Blood. 2022;140(Supplement 1):1844–6. https://doi.org/10.1182/blood-2022-168842.CrossRef

18.

Costa LJ, et al. Minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma (MASTER): final report of the multicentre, single-arm, phase 2 trial. Lancet Haematol. 2023. https://doi.org/10.1016/S2352-3026(23)00236-3.CrossRefPubMed

19.

Sonneveld P, et al. Bortezomib, lenalidomide, and dexamethasone (VRd) ± daratumumab (DARA) in patients (pts) with transplant-eligible (TE) newly diagnosed multiple myeloma (NDMM): A multicenter, randomized, phase III study (PERSEUS). J Clin Oncol. 2019;37(15_suppl):TPS8055. https://doi.org/10.1200/JCO.2019.37.15_suppl.TPS8055.CrossRef

20.

Royle K-L, et al. Risk and response adapted therapy following autologous stem cell transplant in patients with newly diagnosed multiple myeloma (RADAR (UK-MRA myeloma XV trial): study protocol for a phase II/III randomised controlled trial. BMJ Open. 2022;12(11): e063037. https://doi.org/10.1136/bmjopen-2022-063037.CrossRefPubMedPubMedCentral

21.

Costa LJ, et al. International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials. Leukemia. 2021;35(1):18–30. https://doi.org/10.1038/s41375-020-01012-4.CrossRefPubMed

22.

Maura F et al. Genomic classification and individualized prognosis in multiple myeloma. J Clin Oncol. 2024;JCO.23.01277. https://doi.org/10.1200/JCO.23.01277.

23.

John L, et al. Resolving the spatial architecture of myeloma and its microenvironment at the single-cell level. Nat Commun. 2023;14(1):5011. https://doi.org/10.1038/s41467-023-40584-4.CrossRefPubMedPubMedCentral

24.

Kumar S, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17(8):e328–46. https://doi.org/10.1016/S1470-2045(16)30206-6.CrossRefPubMed

25.

Derman BA. MRD-guided treatment cessation in multiple myeloma. Lancet Haematol. 2023. https://doi.org/10.1016/S2352-3026(23)00240-5.CrossRefPubMed

26.

Maclachlan KH, et al. Minimal residual disease in multiple myeloma: defining the role of next generation sequencing and flow cytometry in routine diagnostic use. Pathology. 2021;53(3):385–99. https://doi.org/10.1016/j.pathol.2021.02.003.CrossRefPubMed

27.

Puig N, Flores-Montero J, Jimenez C, Sarasquete M-E, Garcia-Alvarez M, Prieto-Conde I, Chillon C, Alcoceba M, Gutierrez NC, Oriol A, Medina A, Bladè J, Gironella M, Hernandez MT, Gonzalez-Calle V, Cedena M-T, Paiva B, San-Miguel JF, Lahuerta J-J, Mateos M-V, Rosinol L, Orfao A, Gonzalez M, Garcia-Sanz R, Martinez-Lopez J. Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma. Blood Cancer J. 2020;10(10):108. Accessed: Oct. 03, 2023. [Online]. Available: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7603393/.

28.

Roshal M, et al. MRD detection in multiple myeloma: comparison between MSKCC 10-color single-tube and EuroFlow 8-color 2-tube methods. Blood Adv. 2017;1(12):728–32. https://doi.org/10.1182/bloodadvances.2016003715.CrossRefPubMedPubMedCentral

29.

Oliva S, et al. Multiparameter flow cytometry (MFC) and next generation sequencing (NGS) for minimal residual disease (MRD) evaluation: results of the FORTE trial in newly diagnosed multiple myeloma (MM). J Clin Oncol. 2020;38(15_suppl):8533. https://doi.org/10.1200/JCO.2020.38.15_suppl.8533.CrossRef

30.

Fonseca R, et al. Integrated analysis of next generation sequencing minimal residual disease (MRD) and PET scan in transplant eligible myeloma patients. Blood Cancer J. 2023;13(1):32. https://doi.org/10.1038/s41408-023-00794-x.CrossRefPubMedPubMedCentral

31.

Rasche L, et al. Combination of flow cytometry and functional imaging for monitoring of residual disease in myeloma. Leukemia. 2019;33(7):1713. https://doi.org/10.1038/S41375-018-0329-0.CrossRefPubMed

32.

Rasche L, et al. Low expression of hexokinase-2 is associated with false-negative FDG–positron emission tomography in multiple myeloma. Blood. 2017;130(1):30–4. https://doi.org/10.1182/BLOOD-2017-03-774422.CrossRefPubMedPubMedCentral

33.

Ulaner GA, Landgren CO. Current and potential applications of positron emission tomography for multiple myeloma and plasma cell disorders. Best Pract Res Clin Haematol. 2020;33(1): 101148. https://doi.org/10.1016/J.BEHA.2020.101148.CrossRefPubMedPubMedCentral

34.

Ulaner GA, et al. CD38-targeted immuno-PET of multiple myeloma: From xenograft models to first-in-human imaging. Radiology. 2020;295(3):606–15. https://doi.org/10.1148/RADIOL.2020192621/ASSET/IMAGES/LARGE/RADIOL.2020192621.FIG5.JPEG.CrossRefPubMed

35.

Kraus S, et al. Reduced splenic uptake on 68Ga-Pentixafor-PET/CT imaging in multiple myeloma - a potential imaging biomarker for disease prognosis. Theranostics. 2022;12(13):5986. https://doi.org/10.7150/THNO.75847.CrossRefPubMedPubMedCentral

36.

San-Miguel J, et al. Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE. Blood. 2022;139(4):492–501. https://doi.org/10.1182/blood.2020010439.CrossRefPubMedPubMedCentral

37.

Coffey DG, et al. Immunophenotypic correlates of sustained MRD negativity in patients with multiple myeloma. Nat Commun. 2023;14(1):5335. https://doi.org/10.1038/s41467-023-40966-8.CrossRefPubMedPubMedCentral

38.

Maura F, et al. Genomic and immune signatures predict clinical outcome in newly diagnosed multiple myeloma treated with immunotherapy regimens. Nat Cancer. 2023;4(12):1660–74. https://doi.org/10.1038/s43018-023-00657-1.CrossRefPubMed

39.

Derman BA, Fonseca R. Measurable residual disease and decision-making in multiple myeloma. Hematol Oncol Clin North Am. 2024. https://doi.org/10.1016/j.hoc.2023.12.009.CrossRefPubMed

40.

Brown S, et al. MUKnine OPTIMUM protocol: a screening study to identify high-risk patients with multiple myeloma suitable for novel treatment approaches combined with a phase II study evaluating optimised combination of biological therapy in newly diagnosed high-risk multiple myeloma and plasma cell leukaemia. BMJ Open. 2021;11(3): e046225. https://doi.org/10.1136/BMJOPEN-2020-046225.CrossRefPubMedPubMedCentral

41.

Derman BA, Kansagra A, Zonder J, Stefka AT, Grinblatt DL, Anderson Jr LD et al. Elotuzumab and weekly carfilzomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma without transplant intent. JAMA Oncol. 2022;8(9):1278–1286. Accessed: Oct. 08, 2023. [Online]. Available: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9305600/.

42.

Richardson PG, et al. Triplet therapy, transplantation, and maintenance until progression in myeloma. N Engl J Med. 2022;387(2):132–47. https://doi.org/10.1056/NEJMoa2204925.CrossRefPubMedPubMedCentral

43.

Perrot A, et al. Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma. Blood. 2018;132(23):2456–64. https://doi.org/10.1182/blood-2018-06-858613.CrossRefPubMedPubMedCentral

44.

Perrot A, et al. Early versus late autologous stem cell transplant in newly diagnosed multiple myeloma: long-term follow-up analysis of the IFM 2009 trial. Blood. 2020;136(Supplement 1):39. https://doi.org/10.1182/blood-2020-134538.CrossRef

45.

Landgren O, et al. Safety and effectiveness of weekly carfilzomib, lenalidomide, dexamethasone, and daratumumab combination therapy for patients with newly diagnosed multiple myeloma: the MANHATTAN nonrandomized clinical trial. JAMA Oncol. 2021;7(6):862–8. https://doi.org/10.1001/jamaoncol.2021.0611.CrossRefPubMedPubMedCentral

46.

Attal M, et al. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N Engl J Med. 2012;366(19):1782–91. https://doi.org/10.1056/NEJMoa1114138.CrossRefPubMed

47.

Palumbo A, et al. Continuous lenalidomide treatment for newly diagnosed multiple myeloma. N Engl J Med. 2012;366(19):1759–69. https://doi.org/10.1056/NEJMoa1112704.CrossRefPubMed

48.

McCarthy PL, et al. Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med. 2012;366(19):1770–81. https://doi.org/10.1056/NEJMoa1114083.CrossRefPubMedPubMedCentral

49.

Jones JR, et al. Maintenance lenalidomide in newly diagnosed transplant eligible and non-eligible myeloma patients; profiling second primary malignancies in 4358 patients treated in the Myeloma XI Trial. EClinicalMedicine. 2023;62: 102099. https://doi.org/10.1016/j.eclinm.2023.102099.CrossRefPubMedPubMedCentral

50.

Marchetti M, Gale RP, Barosi G. Cost-effectiveness of post-autotransplant lenalidomide in persons with multiple myeloma. Mediterr J Hematol Infect Dis. 2021;13(1):2021034. https://doi.org/10.4084/MJHID.2021.034.CrossRef

51.

Diamond B, et al. Tracking the evolution of therapy-related myeloid neoplasms using chemotherapy signatures. Blood. 2023;141(19):2359–71. https://doi.org/10.1182/blood.2022018244.CrossRefPubMed

52.

Geyer MB, et al. Lenalidomide-associated B-cell ALL: clinical and pathologic correlates and sensitivity to lenalidomide withdrawal. Blood Adv. 2023;7(13):3087–98. https://doi.org/10.1182/bloodadvances.2022009212.CrossRefPubMedPubMedCentral

53.

Nadeem O, et al. Phase II trial of daratumumab, bortezomib, lenalidomide and dexamethasone in high-risk smoldering multiple myeloma. Blood. 2023;142:3382. https://doi.org/10.1182/blood-2023-177947.CrossRef

54.

Pawlyn C, et al. Defining the optimal duration of lenalidomide maintenance after autologous stem cell transplant - data from the myeloma XI trial. Blood. 2022;140(Supplement 1):1371–2. https://doi.org/10.1182/blood-2022-165376.CrossRef

55.

Kendrick S, Szabo A, Yarlagadda N, Atwal D, Pandey Y, Roy A, Parikh R, Lopez J, Thanendrarajan S, Schinke C, Alapat D, Mohan M, Tian E, Tricot G, van Rhee F, Zangari M, Sawyer J. Clinical implications of loss of bone marrow minimal residual disease negativity in multiple myeloma. Blood Adv. 2021;6(3):808–817. Accessed: Oct. 04, 2023. [Online]. Available: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8945288/.

56.

Kumar S. Don’t let the genie out of the bottle! Blood. 2024;143(7):564–6. https://doi.org/10.1182/blood.2023023293.CrossRefPubMed

57.

D’Agostino M, et al. Predictors of unsustained measurable residual disease negativity in patients with multiple myeloma. Blood. 2024;143(7):592–6. https://doi.org/10.1182/blood.2023022080.CrossRefPubMed

58.

Guerrero C, et al. Predictors of unsustained measurable residual disease negativity in transplant-eligible patients with multiple myeloma. Blood. 2024;143(7):597–603. https://doi.org/10.1182/blood.2023022083.CrossRefPubMed

59.

Rosinol L, et al. Ixazomib plus lenalidomide/dexamethasone (IRd) versus lenalidomide /dexamethasone (Rd) maintenance after autologous stem cell transplant in patients with newly diagnosed multiple myeloma: results of the Spanish GEM2014MAIN trial. Blood. 2021;138(Supplement 1):466. https://doi.org/10.1182/blood-2021-146798.CrossRef

60.

Dytfeld D, et al. Carfilzomib, lenalidomide, and dexamethasone or lenalidomide alone as maintenance therapy after autologous stem-cell transplantation in patients with multiple myeloma (ATLAS): interim analysis of a randomised, open-label, phase 3 trial. Lancet Oncol. 2023;24(2):139–50. https://doi.org/10.1016/S1470-2045(22)00738-0.CrossRefPubMedPubMedCentral

Title: Minimal Residual Disease-Adapted Therapy in Multiple Myeloma: Current Evidence and Opinions
Authors: Mina Meseha
James Hoffman
Dickran Kazandjian
Ola Landgren
Benjamin Diamond
Publication date: 27-04-2024
Publisher: Springer US
Keyword: Multiple Myeloma
Published in: Current Oncology Reports
Print ISSN: 1523-3790
Electronic ISSN: 1534-6269
DOI: https://doi.org/10.1007/s11912-024-01537-2

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose of Review

Recent Findings

Summary

Please log in to get access to this content

Keynote webinar | Spotlight on antibody–drug conjugates in cancer